Latest Treatment of schizophrenia Stories
WILMINGTON, Del., April 3 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) is aware that earlier today, the US Food and Drug Administration (FDA) posted to its web site -- and subsequently removed -- briefing documents for the April 8, 2009 Psychopharmacologic Drugs Advisory Committee (PDAC) meeting.
SAN DIEGO, March 29 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced today inconclusive Phase II clinical trial results from Study HBBI investigating LY2140023 monohydrate, also known as mGlu2/3, for the treatment of patients suffering from acute schizophrenia.
ROCKVILLE, Md., March 10 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc.
A Canadian researcher suggests that some with schizophrenia may be helped by looking at individual biochemistry, nutrient deficiency, diet and allergies. Dr.
TITUSVILLE, N.J., Feb. 10 /PRNewswire-FirstCall/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
INDIANAPOLIS, Jan. 7 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced today that it received a complete response letter from the U.S.
INDIANAPOLIS, Oct. 21 /PRNewswire-FirstCall/ -- Eli Lilly and Company today announced that it is in advanced discussions to resolve the ongoing investigations led by the U.S. Attorney's Office for the Eastern District of Pennsylvania (EDPA) related to past U.S.
Alkermes, a biotechnology company, has announced that patients with schizophrenia now have a new administration option for Risperdal Consta. The FDA has approved a new injection site, the deltoid muscle in the arm, for Risperdal Consta for the treatment of patients with schizophrenia.
- A volcanic mudflow.